Recent Quotes
My Watchlist
Indicators
Local Stocks
Buffalo Local Index
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Bluebird Bio (NQ: BLUE )

31.10 USD +2.98 (+10.60%)
Official Closing Price Updated: 7:59 PM EST, Feb 26, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 5,898,000
Open 28.24
Bid (Size) 30.34 (1)
Ask (Size) 30.90 (1)
Prev. Close 28.12
Today's Range 27.43 - 31.14
52wk Range 24.24 - 76.00
Shares Outstanding 50,119,272
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
DEADLINE ALERT for BLUE, EH, JT, and IMVT: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
From GlobeNewswire News Releases
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against iRhythm Technologies, Tyson Foods, Clover Health Investments, and bluebird bio and Encourages Investors
From GlobeNewswire News Releases

Performance

YTD
-30.36%
-30.36%
1 Month
-33.50%
-33.50%
3 Month
-29.41%
-29.41%
6 Month
-45.20%
-45.20%
1 Year
-53.43%
-53.43%

More News

Read More
LAWSUITS FILED AGAINST BLUE, CLOV and APA - Jakubowitz Law Pursues Shareholders Claims
From ACCESSWIRE
Breaking Notice: Rosen, a Globally Recognized Law Firm, Encourages bluebird bio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline – BLUE
From Business Wire News Releases
bluebird bio to Present at Cowen Health Care Conference
From Business Wire News Releases
BLUE ALERT: Pawar Law Group Announces a Securities Class Action Lawsuit Against bluebird bio, Inc.– BLUE
From GlobeNewswire News Releases
The New England Journal of Medicine Publishes Results from Pivotal Phase 2 KarMMa Study of Idecabtagene Vicleucel (Ide-cel, bb2121), an Investigational BCMA-Directed CAR T Cell Therapy
From Business Wire News Releases
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against bluebird bio, Inc. (BLUE)
From Business Wire News Releases
bluebird bio Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Operational Progress
From Business Wire News Releases
Magenta Is Ready to Paint Your Portfolio Green
Tags Market News BLUE MGTA
From Motley Fool
BLUE SHAREHOLDER FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Has Been Filed Against bluebird bio, Inc
From GlobeNewswire News Releases
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.